Background
==========

History of kampo medicine
-------------------------

Kampo medicines are traditional Japanese medicines produced from medicinal plants and herbs. Kampo originates from China and has been adapted to the Japanese culture \[[@B1]\]. Chinese herbal medicine was imported to Japan in 552 AD, after which it was uniquely developed into Japanese Kampo \[[@B2]\]. Traditional Chinese Medicine is deeply philosophical and ideological, while Japanese Kampo tends to be more practical and simplified, and relies little on Taoist or other Chinese philosophy \[[@B2]\].

Kampo medicines are currently of great interest to palliative care physicians because of their potential to alleviate the adverse side effects of cancer treatment and improve patients' quality of life.

Use of Kampo and CAM in Japan
-----------------------------

In the past few decades, Kampo has reintegrated into modern medical practice, accompanied by a scientific reevaluation and critical examination of its relevance in conventional medicine \[[@B2],[@B3]\]. Kampo has been used in addition or alternatively to conventional medicines \[[@B4]\]. Currently more than 70% of Japanese physicians prescribe Kampo medicines in daily clinical practices \[[@B5]\]. Previous survey research has reported that 76% of the general population in Japan and 50% of outpatients in Tokyo have used some form of CAM and that 10% of the general population and 19% of outpatients in Tokyo had used Kampo medicine prescribed by physicians within the last 12 months \[[@B6],[@B7]\]. In addition, the prevalence of use of CAM by cancer patients was 44.6% in Japan \[[@B8]\]. Internationally, the estimates of CAM use are higher in East Asia and highest in Japan compared to the USA and European countries \[[@B9],[@B10]\]. CAM is often used in palliative care settings where the goal is not cure but rather improvement in QOL \[[@B10]\].

To date, the Ministry of Health, Labour and Welfare (MHLW) has approved the use of 148 Kampo medicines, and the prescription of Kampo medicines is within the national health insurance system \[[@B3],[@B11]\]. Although Kampo can be seen as orthodox from a historical Japanese perspective, it tends to be classified as Complementary and Alternative Medicine (CAM) according to Western conventions. The main reason for this is the lack of scientific evidence of its efficacy and the limited knowledge and spread of this therapy in other regions, especially outside of East Asia.

However, clinical studies of Kampo have been conducted in Japan, and its efficacy has been reported in research papers. For example, a randomized control trial demonstrated that the Kampo medicine *Rikkunshito* exerted greater effects in alleviating gastrointestinal symptoms than cisapride (a gastroprokinetic agent) \[[@B12]\]. The efficacy of *Rikkunshito* against non-ulcer dyspepsia (NUD) \[[@B13],[@B14]\], gastrointestinal symptoms after gastrectomy (surgical NUD) \[[@B15]\], functional dyspepsia \[[@B16],[@B17]\], and nausea and vomiting caused by selective serotonin reuptake inhibitors \[[@B18]\] has also been reported. Also, the Japanese Society for Oriental Medicine has compiled comprehensive data on randomized controlled trials of Kampo medicine in Japan, published as "Evidence Reports of Kampo Treatment" (EKAT) \[[@B19]\]. In addition to clinical trials, the potential mechanisms of action of Kampo medicines are also starting to be reported \[[@B20]\].

As described above, there is increasing evidence of the efficacy of Kampo medicines and increasing attention has been given to their clinical application. However, there has been no comprehensive investigation of the use of Kampo medicines in cancer treatment. Therefore, we conducted a nationwide survey of the current use of Kampo medicines for cancer-related treatment and of physicians' attitudes toward using Kampo medicines in Japan.

Methods
=======

Study sample and data collection
--------------------------------

The survey was carried out between January and March of 2011, by mailing a self-administered anonymous questionnaire to 549 palliative care physicians who administer chemotherapy to cancer patients or who are involved in their terminal care. The palliative care teams in 388 core cancer treatment hospitals and 161 palliative care units (PCUs) within medical institutions were selected because they represent palliative care practice in Japan. This included all core cancer treatment hospitals and PCUs in Japan as of February 2011. Core cancer treatment hospitals are the medical facilities specified by the MHLW to provide high-quality expert care for cancer patients. These facilities are established within each prefecture in Japan, according to the principles set forth in the Cancer Control Act promulgated in April 2007. The contact information of subjects was obtained from a web site of the Cancer Control Information Center, National Cancer Center \[[@B21]\].

We did not specifically include general internists or surgeons who are not in charge of palliative care as subjects of the survey. This is because the certification system for the palliative care specialist is still immature in Japan and the attending physicians of palliative care teams and PCUs are often internists or surgeons.

Questionnaire development
-------------------------

An eight-page, 18-item questionnaire was designed in Japanese. It covered four categories: (1) status of cancer treatment and use of Kampo medicines, (2) cancer cachexia and utilization of Kampo medicines (data not shown), (3) adverse side effects of anti-cancer drugs and utilization of Kampo medicines, and (4) background variables. Although the questionnaire was not formally validated, the questionnaire and its items were designed and formulated based upon the expert opinions of specialists from palliative care, medical oncology, Kampo medicine, and biological statistics, and also from literature reviews. It was finalized after testing several samples.

Ethical considerations
----------------------

We conducted this research in compliance with the Helsinki Declaration. We had requested an ethical review of this research from the ethical review committee of the National Cancer Center prior to commencement. However, since this research involves neither patients' data nor intervention, the committee judged that this research should not be subjected to any Japanese medical research guidelines. Accordingly, the research was exempt from the requirement for formal ethical approval.

To ensure that informed consent was obtained, the questionnaire was sent to the physicians with a leaflet explaining the survey's objectives and that (1) each subject was free to decide whether or not to answer the questions; (2) the collected data will be processed and analyzed anonymously; and (3) the data will be securely archived by the Research Secretariat. Consent was implied through the return of a completed questionnaire.

Data analysis
-------------

The collected data were entered into an electronic database and analyzed using SPSS (IBM, New York, USA). Chi-squared tests (p value \< 0.050) were conducted to compare the frequency distributions of two cross-tabulations. The first was physicians in the palliative care teams at the core cancer treatment hospitals compared with physicians in the PCUs. The second was the palliative care specialists certified by the Japan Society of Palliative Medicine (JSPM) compared with non-specialists.

Results and discussion
======================

Of the 549 questionnaires distributed, 311 valid responses were collected for analysis (response rate, 56.7%). Responses were obtained from 226 physicians (response rate, 58.2%) at core cancer treatment hospitals (palliative care team physicians) and 79 physicians (response rate, 49.1%) from PCUs (PCU physicians). With the moderate rate of valid responses (56.7%), the respondents were well-distributed throughout the country, without significant geographical biases. Table [1](#T1){ref-type="table"} shows the response rates and the respondents' background characteristics. Two hundred thirty seven respondents (77.9%) were aged between 40 and 59 years. Two hundred seventy three respondents (90.1%) were male, and 128 respondents (41.2%) were JSPM-authorized palliative care specialists (including provisional medical advisors).

###### 

Respondents' background characteristics

  **Respondents (n = 311)**                                                            **Average ± SD**   **Minimum value**   **Maximum value**                     
  -------------------------------------------------------- ------------------ ------- ------------------ ------------------- ------------------- --------- -----------------
  Age                                                                                       49 ± 8               28                  75                             
  Years of experience                                                                       23 ± 8                4                  50                             
                                                                                          Responses              \%                                                 
  Institution (n = 549) \*                                                                                                                                          
   Core cancer treatment hospital (n = 388)                                                  226                58.2                                                
   Palliative Care Unit in medical institution (n = 161)                        79           49.1                                                          
                                                                                              n                  \%                                                 
  Age group                                                                                                                                                         
   20--29 years                                                                               1                  0.3                                                
   30--39 years                                                                               39                12.8                                                
   40--49 years                                                                              119                39.1                                                
   50--59 years                                                                              118                38.8                                                
   ≥ 60 years                                                                                 27                 8.9                                                
  Sex                                                                                                                                                               
   Male                                                                                      273                90.1                                                
   Female                                                                                     30                 9.9                                                
  Palliative Care Specialists certified by JSPM\*\*                                                                                                        
   Specialists (including provisional medical advisors)                         128          41.2                                                          
   Non-specialists                                                                           183                58.8                                                
  Region\*\*\*                                              Hokkaido--Tohoku   Kanto        Chubu               Kinki              Chugoku        Shikoku   Kyushu--Okinawa
   Number of questionnaires distributed                            79           116           92                 91                  47             27            97
   Number of responses                                             26           43            41                 33                  25             11            37
   Response rate (%)                                              32.9         37.1          44.6               36.3                53.2           40.7          38.1

\*Six responses had missing institution data, and \*\*\*95 responses had missing region data.

\*\* JSPM: Japan Society for Palliative Medicine.

Difficult to treat cancer-related symptoms
------------------------------------------

Physicians were asked to identify which of the 23 common cancer-related symptoms that they find difficult to treat (Table [2](#T2){ref-type="table"}). More than 50% of the physicians identified *numbness/hypoesthesia* (n = 240, 77.2%), *languor/fatigue* (n = 225, 72.3%), *delirium* (N = 170, 54.7%), and *taste alteration* (n = 166, 53.4%). In comparison with the PCU physicians, more palliative care team physicians identified *taste alteration* (p = 0.029), *nausea/vomiting (during chemotherapy)* (p = 0.000), and *constipation (caused by opioid use)* (p = 0.038). More of the PCU physicians, on the other hand, reported having difficulty treating *adjustment disorder* (p = 0.014). In addition, the symptoms of *taste alteration* (p = 0.050), *dysphagia/deglutition disorder* (p = 0.036) and *muscle weakness* (p = 0.047) were identified as being difficult to treat more often by the palliative care specialists than the non-specialists.

###### 

Difficult to treat cancer-related symptoms identified by physicians

                **Symptoms**                 **All physicians (n = 311)**   **Palliative care teams (n = 226)**   **PCUs (n = 79)**   **p-value**   **Specialists (n = 128)**   **Non-specialists (n = 183)**   **p-value**                    
  ----------------------------------------- ------------------------------ ------------------------------------- ------------------- ------------- --------------------------- ------------------------------- ------------- ---- ------ ----- ------
            Numbness/Hypesthesia                         240                               77.2                          180             79.6                  55                           69.6                   0.165      99   77.3   141   77.0
               Languor/Fatigue                           225                               72.3                          161             71.2                  61                           77.2                   0.276      99   77.3   126   68.9
                  Delirium                               170                               54.7                          119             52.7                  48                           60.8                   0.447      73   57.0   97    53.0
              Taste alteration                           166                               53.4                          124             54.9                  42                           53.2                   0.029      77   60.2   89    48.6
        Edema (Local edema/Anasarca)                     150                               48.2                          109             48.2                  39                           49.4                   0.821      59   46.1   91    49.7
                    Pain                                 146                               46.9                          113             50.0                  31                           39.2                   0.226      55   43.0   91    49.7
            Anorexia/Weight loss                         140                               45.0                          109             48.2                  30                           38.0                   0.108      64   50.0   76    41.5
            Abdominal discomfort                         131                               42.1                          98              43.4                  31                           39.2                   0.735      55   43.0   76    41.5
            Stomatitis/Xerostomia                        122                               39.2                          89              39.4                  33                           41.8                   0.141      54   42.2   68    37.2
                 Depression                              116                               37.3                          86              38.1                  30                           38.0                   0.175      41   32.0   75    41.0
             Adjustment disorder                         113                               36.3                          73              32.3                  39                           49.4                   0.014      47   36.7   66    36.1
           Dyspnea/Breathlessness                        113                               36.3                          77              34.1                  35                           44.3                   0.162      48   37.5   65    35.5
           Nausea/Vomiting (other)                       101                               32.5                          75              33.2                  24                           30.4                   0.893      38   29.7   63    34.4
       Dysphagia/Deglutition disorder                    100                               32.2                          68              30.1                  31                           39.2                   0.281      50   39.1   50    27.3
           Sleep disorder/Insomnia                        93                               29.9                          69              30.5                  23                           29.1                   0.796      42   32.8   51    27.9
     Constipation (caused by opioid use)                  84                               27.0                          69              30.5                  15                           19.0                   0.038      34   26.6   50    27.3
    Nausea/Vomiting (during chemotherapy)                 76                               24.4                          71              31.4                   5                            6.3                   0.000      27   21.1   49    26.8
               Muscle weakness                            65                               20.9                          46              20.4                  19                           24.1                   0.346      34   26.6   31    16.9
   Nausea/Vomiting (caused by opioid use)                 61                               19.6                          51              22.6                  10                           12.7                   0.690      24   18.8   37    20.2
   Constipation (not caused by opioid use)                59                               19.0                          47              20.8                  11                           13.9                   0.377      28   21.9   31    16.9
                Muscle cramp                              42                               13.5                          31              13.7                  11                           13.9                   0.741      23   18.0   19    10.4
                  Diarrhea                                40                               12.9                          34              15.0                   6                            7.6                   0.136      16   12.5   24    13.1
                   Anemia                                 29                                9.3                          24              10.6                   5                            6.3                   0.344      16   12.5   13    7.1
                   Others                                 11                                3.5                           6               2.7                   5                            6.3                   0.325      4    3.1     7    3.8

Multiple answers allowed, p-value based on Chi-square test.

Numbness is a neuropathic symptom that frequently occurs as an adverse side effect of chemotherapy. It has been reported to account for 58% of all neurological symptoms experienced by cancer patients \[[@B22]\]. Fatigue is the most common cancer symptom \[[@B23]\], and was reported by 66% of patients in a previous study \[[@B22]\]. The prevalence of delirium is 25--40% (85--88% in the terminal stage of cancer) \[[@B24]-[@B26]\], and the prevalence of taste alteration is 36--75% among patients receiving chemotherapy \[[@B27]\]. Thus, it was shown in the present survey that the symptoms palliative care physicians have difficulty managing in Japan are those frequently seen in cancer patients.

We also found that the palliative care team physicians confront *taste alteration* (p = 0.029), *nausea/vomiting during chemotherapy* (p = 0.000) and *constipation during opioid use* (0.038) more often than the PCU physicians (Table [2](#T2){ref-type="table"}). These facts suggest that the palliative care teams are often in charge of patients receiving chemotherapy, while PCUs are more frequently dealing with psychiatric symptoms than the adverse side effects of chemotherapy.

Prescription of Kampo medicines
-------------------------------

Kampo medicines were being prescribed by 64.3% (n = 200) of the physicians to alleviate the cancer patients' symptoms. Kampo medicines were prescribed to control *numbness/hypoesthesia* (n = 99, 49.5%), *constipation (not caused by opioid use)* (n = 76, 38%), *anorexia/weight loss* (n = 72, 36%), *muscle cramps* (n = 71, 35.5%), and *languor/fatigue* (n = 64, 32%) by more than 30% of the physicians (Table [3](#T3){ref-type="table"}). The palliative care team physicians prescribed Kampo medicines for *numbness/hypoesthesia* (p = 0.000), *anorexia/weight loss* (p = 0.046), *pain* (p = 0.020), and *nausea/vomiting during chemotherapy* (p = 0.016), more frequently than the PCU physicians. This difference may arise because the palliative care teams more often examine patients who are under chemotherapy than the PCUs, and thus they pay more attention than the PCUs to the necessity of controlling the adverse side effects of chemotherapy. Also, PCU patients have more difficulty taking Kampo medicines than the general hospital patients under the palliative care teams. The frequency of prescribing Kampo medicines did not vary significantly across the symptoms between the palliative care specialists and non-specialists.

###### 

Symptoms for which Kampo medicines were prescribed

  **Symptoms**                               **All physicians (n = 200)**   **Palliative care teams (n = 149)**   **PCUs (n = 46)**   **p-value**              
  ----------------------------------------- ------------------------------ ------------------------------------- ------------------- ------------- ---- ------ -------
  Numbness/Hypesthesia                                    99                               49.5                          86              57.7       12   26.1   0.000
  Constipation (not caused by opioid use)                 76                                38                           56              37.6       20   43.5   0.182
  Anorexia/Weight loss                                    72                                36                           60              40.3       12   26.1   0.046
  Muscle cramp                                            71                               35.5                          54              36.2       17   37.0   0.279
  Languor/Fatigue                                         64                                32                           49              32.9       14   30.4   0.818
  Constipation (caused by opioid use)                     48                                24                           37              24.8       11   23.9   0.490
  Abdominal discomfort                                    46                                23                           29              19.5       16   34.8   0.088
  Diarrhea                                                45                               22.5                          39              26.2       5    10.9   0.090
  Delirium                                                40                                20                           27              18.1       13   28.3   0.155
  Pain                                                    38                                19                           35              23.5       3    6.5    0.020
  Edema (Local edema/Anasarca)                            31                               15.5                          25              16.8       6    13.0   0.546
  Nausea/Vomiting (other)                                 27                               13.5                          22              14.8       5    10.9   0.566
  Nausea/Vomiting (during chemotherapy)                   22                                11                           22              14.8       0    0.0    0.016
  Stomatitis/Xerostomia                                   21                               10.5                          19              12.8       2    4.3    0.216
  Taste alteration                                        20                                10                           17              11.4       3    6.5    0.409
  Depression                                              20                                10                           17              11.4       3    6.5    0.409
  Nausea/Vomiting (caused by opioid use)                  17                                8.5                          16              10.7       1    2.2    0.129
  Adjustment disorder                                     15                                7.5                          12               8.1       3    6.5    0.846
  Sleep disorder/Insomnia                                 14                                 7                           10               6.7       4    8.7    0.823
  Others                                                  13                                6.5                           6               4.0       6    13.0   0.055
  Anemia                                                  11                                5.5                           9               6.0       2    4.3    0.805
  Dysphagia/Deglutition disorder                          10                                 5                            9               6.0       1    2.2    0.581
  Dyspnea/Breathlessness                                  6                                  3                            5               3.4       1    2.2    1.000
  Muscle weakness                                         3                                 1.5                           3               2.0       0    0.0    0.614

Multiple answers allowed, p-value based on Chai-square test.

Reasons for prescription
------------------------

More than 60% of the physicians prescribed Kampo medicines for the following reasons: 'the drug therapy options are greater' (n = 144, 72%), 'ineffectiveness of other treatments' (n = 129, 64.5%), and 'unavailability of other appropriate treatments' (n = 127, 63.5%). Although 'patient demand' was the least frequent reason (n = 46, 23%), palliative care specialists were more attentive to patients' demands than non-specialists (n = 28, 37.3%, p = 0.000).

Variety and frequency of prescriptions
--------------------------------------

Eight Kampo medicines were selected from the literature reviews to investigate frequency of prescription. Table [4](#T4){ref-type="table"} shows the composition of each Kampo medicine \[[@B28]-[@B30]\].*Daikenchuto* was the most frequently prescribed (n = 140, 70%) among eight major Kampo medicines (Table [5](#T5){ref-type="table"}). This is probably because the efficacy of *Daikenchuto* for the treatment of gastrointestinal symptoms is currently being tested in clinical trials in Japan and the United States. A tolerability and efficacy phase II study of *Daikenchuto* for the treatment of postoperative ileus has been already completed in the United States \[[@B31]\]. This might encourage its prescription by physicians. The palliative care team physicans prescribed *Goshajinkigan* (p = 0.000)*, Rikkunshito* (p = 0.001)*, Hochuekkito* (p = 0.011)*, Juzentaihoto* (p = 0.001), and *Hangeshashinto* (p = 0.000) more frequently than PCU physicians, while there were no significant differences in the medicines prescribed between the palliative care specialists and non-specialists.

###### 

Composition of Kampo medicines

   **Kampo Medicine**   **Ingredients (crude drugs)**                                                                                                                                                                                                                          
  -------------------- ------------------------------- ------------------------------ ------------------------------ ---------------------------- ------------------- ------------------------------ ------------------------------ -------------------- --------------------- ------------------------
     Hangeshashinto            Pinelliae Tuber               Scutellariae Radix        Zingiberis Processum Rhizoma       Glycyrrhizae Radix        Zizyphi Fructus           Ginseng Radix                 Coptidis Rhizoma                                                               
      Hochuekkito              Astragali Radix          Atractylodis lanceae Rhizoma          Ginseng Radix                Angelicae Radix          Bupleuri Radix           Zizyphi Fructus          Aurantii Nobilis Pericarpium   Glycyrrhizae Radix   Cimicifugae Rhizoma     Zingiberis Rhizoma
      Rikkunshito       Atractylodis lanceae Rhizoma           Ginseng Radix                 Pinelliae Tuber                    Poria               Zizyphi Fructus    Aurantii Nobilis Pericarpium        Glycyrrhizae Radix        Zingiberis Rhizoma                                    
      Juzentaihoto             Astragali Radix                Cinnamomi Cortex               Rehmanniae Radix               Paeoniae Radix          Cnidii Rhizoma     Atractylodis lanceae Rhizoma         Angelicae Radix            Ginseng Radix             Poria            Glycyrrhizae Radix
       Yokukansan       Atractylodis lanceae Rhizoma               Poria                      Cnidii Rhizoma          Uncariae Uncis cum Ramulus    Angelicae Radix           Bupleuri Radix               Glycyrrhizae Radix                                                              
    Shakuyakukanzoto         Glycyrrhizae Radix                Paeoniae Radix                                                                                                                                                                                                              
      Daikenchuto       Zingiberis Processum Rhizoma           Ginseng Radix                Zanthoxyli Fructus                                                                                                                                                                             
     Goshajinkigan            Rehmanniae Radix               Achyranthis Radix                Corni Fructus               Dioscoreae Rhizoma       Plantaginis Semen        Alismatis Rhizoma                    Poria                 Moutan Cortex       Cinnamomi Cortex     Processi Aconiti Radix

Ingredients of each Kampo medicine were based on the package inserts of Tsumura products \[[@B28]\].

Scientific names of ingredients were based on Metabolomics.jp \[[@B29]\] and The Japanese Pharmacopeia Fifteenth edition \[[@B30]\].

###### 

The Kampo medicines prescribed by the physicians

  **Kampo medicine**    **All physicians (n = 200)**   **Palliative care teams (n = 149)**   **PCUs (n = 46)**   **p-value**              
  -------------------- ------------------------------ ------------------------------------- ------------------- ------------- ---- ------ -------
  Daikenchuto                       140                               70.0                          109             73.2       29   63.0   0.124
  Goshajinkigan                     100                               50.0                          89              59.7       11   23.9   0.000
  Rikkunshito                        97                               48.5                          82              55.0       15   32.6   0.001
  Shakuyakukanzoto                   96                               48.0                          76              51.0       20   43.5   0.069
  Hochuekkito                        90                               45.0                          76              51.0       13   28.3   0.011
  Juzentaihoto                       84                               42.0                          73              49.0       11   23.9   0.001
  Yokukansan                         61                               30.5                          45              30.2       16   34.8   0.253
  Hangeshashinto                     54                               27.0                          51              34.2       3    6.5    0.000
  Others                             24                               12.0                          20              13.4       4    8.7    0.457

Multiple answers allowed, p-value based on Chi-square test.

Physician-recognized effectiveness
----------------------------------

We investigated the physician-recognized effectiveness of eight Kampo medicines. Two symptoms from each Kampo medicine's package insert were listed and the physicians were asked to indicate whether they believed the medicine effectively treated them (Table [6](#T6){ref-type="table"}). More than 50% of the physicians recognized the effectiveness of *Hangeshashinto* against *diarrhea caused by chemotherapy* (n = 31, 53.4%), of *Hochuekkito* and *Juzentaihoto* against *fatigue* (n = 54, 56.3% and n = 50, 56.8% respectively), of *Rikkunshito* against *anorexia* (n = 46, 50%), of *Yokukansan* against *delirium* (n = 38, 63.3%), of *Shakuyakukanzoto* against *leg cramps* (n = 79, 82.3%)*,* and of *Daikenchuto* against *ileus* (n = 101, 78.9%) and *opioid-caused constipation and abdominal pain* (n = 62, 53.9%). There was no significant difference in the medicines recognized as effective between the palliative care team and PCU physicians, while the palliative care specialists seemed to be more aware of the effectiveness of *Rikkunshito* against *nausea* than non-specialists (p = 0.012) (Table [6](#T6){ref-type="table"}). These results suggest that there is consensus among palliative care physicians regarding the effectiveness of particular Kampo medicines against particular symptoms.

###### 

Physician-recognized effectiveness of Kampo medicines

  **Kampo medicine**                    **Symptoms**                    **Recognized as effective**                                       
  -------------------- ----------------------------------------------- ----------------------------- ------ ------- ------ ------- ------ -------
  Hangeshashinto               Diarrhea caused by chemotherapy                     31/58              53.4   10/22   45.5   21/36   58.3   0.420
                                           Nausea                                  10/45              22.2   3/21    14.3   7/24    29.2   0.296
  Hochuekkito                             Anorexia                                 44/90              48.9   14/36   38.9   30/54   55.6   0.137
                                           Fatigue                                 54/96              56.3   19/39   48.7   35/57   61.4   0.295
  Rikkunshito                              Nausea                                  36/82              43.9   9/34    26.5   27/48   56.3   0.012
                                          Anorexia                                 46/92              50.0   18/40   45.0   28/52   53.8   0.528
  Juzentaihoto                             Fatigue                                 50/88              56.8   17/33   51.5   33/55   60.0   0.508
                          AE caused by chemotherapy or radiotherapy                27/58              46.6   7/22    31.8   20/36   55.6   0.106
  Yokukansan                              Delirium                                 38/60              63.3   18/26   69.2   20/34   58.8   0.433
                                           Anxiety                                 15/50              30.0   6/23    26.1   9/27    33.3   0.758
  Shakuyakukanzoto                       Leg cramps                                79/96              82.3   36/43   83.7   43/53   81.1   0.794
                                       Abdominal pain                              20/57              35.1   11/25   44.0   9/32    28.1   0.268
  Daikenchuto                               Ileus                                 101/128             78.9   35/48   72.9   66/80   82.5   0.263
                        Opioid-caused constipation and abdominal pain             62/115              53.9   22/47   46.8   40/68   58.8   0.254
  Goshajinkigan                  Numbness of hands and feet                       47/107              43.9   18/39   46.2   29/68   42.6   0.840
                                          Nocturia                                 13/60              21.7   4/26    15.4   9/34    26.5   0.358

Multiple answers allowed, p-value based on Chi-square test.

Prescription considerations
---------------------------

In the questionnaire, the physicians were asked, "What are the important considerations when selecting a Kampo medicine for prescription?". More than 80% of the physicians recognized the importance of 'symptom-alleviating effects (alleviation of adverse side effects) (n = 173, 93%)', 'alleviation of symptoms that reduce QOL in the terminal stage of cancer' (n = 162, 87.6%), 'low incidence of adverse side effects' (n = 157, 84.9%) and 'easy to combine with other drugs' (n = 149, 80.5%). The palliative care specialists tended to place more importance than the non-specialists on 'patient demand' (p = 0.050).

Open issues for prescription
----------------------------

The questionnaire also asked the physicians to identify any open issues regarding the prescription of Kampo medicines (Table [7](#T7){ref-type="table"}), revealing that 60.7% (n = 173) of the physicians were concerned that the dose and dosage forms need to be better devised for simpler administration. Kampo medicines are commonly prepared in granule form or as decoctions, and their administration method is nauseating for some patients. This issue may be related to the observation that "patient demand" was chosen least frequently as the reason for prescription. In the clinical field of palliative care, Kampo medicines are often mixed in a jelly for patients who have dysphagia. For future prescriptions, the administration forms need to be better devised from an adherence perspective. The second most frequently identified issue was the lack of scientific evidence for their efficacy, with 38.2% (n = 109) of the physicians highlighting the absence of evidence from placebo-controlled trails. Watanabe *et al.*\[[@B3]\] recently reported a summary of 135 peer-reviewed Kampo trials published between 1988 and 2007. According to their report, 106 trials were RCTs, and only 22 were placebo-controlled trials. In two-thirds of the trials, the sample size was less than 100 patients, and only 35 trials were published in English and the rest were in Japanese. Watanabe *et al.*\[[@B3]\] concluded that the overall quality of the research was low.

###### 

Open issues about prescribing Kampo medicine (n = 285)

  **Issue**                                                                      **frequency**   **%**
  ----------------------------------------------------------------------------- --------------- -------
  The dose and dosage forms need to be better devised for simpler application         173        60.7
  No evidence of efficacy from placebo-controlled studies                             109        38.2
  Action mechanism of Kampo medicine is not yet elucidated                            97         34.0
  No opportunity to learn about Kampo medicines                                       90         31.6
  Relatively weak effect                                                              79         27.7
  Drug interaction is uncertain                                                       66         23.2
  Production of effect is slow                                                        56         19.6
  Others                                                                              25          8.8
  There are no issues                                                                 12          4.2

Multiple answers allowed.

Conclusions
===========

We conducted a nationwide survey of 311 physicians working in palliative care teams at core cancer treatment hospitals and PCUs within medical facilities. Kampo medicines were prescribed by a high proportion (n = 200, 64.3%) of the palliative care physicians and were expected to provide valid means of controlling the cancer patients' symptoms or the adverse side effects of chemotherapy. Palliative care physicians appear to be aware of the effectiveness of Kampo medicines. However, they prescribe Kampo medicines only to a limited extent because of the lack of evidence for their efficacy. Hence, we believe that the collection of more evidence from clinical studies is desirable in Japan.
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